Further Development of INCB7839 as a New Oral Treatment for Breast Cancer
 

Incyte Corporation (Nasdaq:INCY) announced today that three scientific posters have been presented at the 30th San Antonio Breast Cancer Symposium describing the potential benefits of its selective sheddase inhibitor, INCB7839, in the treatment of metastatic breast cancer.


INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. Currently approved therapies that target the EGFR pathways have shown promising efficacy in metastatic disease, validating these pathways as targets; however, efficacy may be limited due to the fact that these drugs inhibit only one or two of the four HER receptor pathways. In contrast, the sheddase inhibitor, INCB7839, has the potential to inhibit activation through all four of the HER receptors, resulting in more complete inhibition of these pathways

full article: http://www.tradingmarkets.com/.site/...20News/918377/

Wow - complete HER pathway blockage!?!
 

This is one drug I want to keep my eye on. The data was a very small study, but more studies are in the works.
From the article:

Data presented at the San Antonio Breast Cancer Symposium demonstrate that INCB7839:
-- has shown promising clinical activity in heavily pretreated, refractory cancer patients
-- has the potential to provide single-agent efficacy as well as improved clinical outcomes when used in combination with other EGFR targeted therapies, including those that target EGFR or HER2
-- has been generally well-tolerated in both preclinical studies and clinical trials
INCB7839 is also currently in Phase II development. The first of two Phase II trials has been initiated and is designed to determine the effectiveness of INCB7839 when used in combination with Herceptin(R). This trial design is based, in part, on the potent synergy demonstrated preclinically with this combination. A second Phase II trial is planned and expected to begin in 2008 that will evaluate INCB7839 as monotherapy.

Looks very interesting. Nice find. Thank you